Biomea Fusion Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
BMEA$0.55-8.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(in thousands, except share data)
| Series A ConvertiblePreferred Stock · Common Stock · Additional Paid-In · AccumulatedOther Comprehensive · Accumulated · TotalStockholders' | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital · Gain (Loss) · Deficit · Equity (Deficit) | ||||||||||||||
| Balance at December 31, 2020 | 7,064,925 | 55,738 | 11,953,107 | $1 | $13,343 | $— | $(8,175) | $5,169 | ||||||
| Series A convertible preferred stock issuance costs | — | (3) | — | — | — | — | — | — | ||||||
| Issuance of common stock from initial public offering, net of issuance costs of $2,557 | — | — | 9,823,532 | 1 | 152,753 | — | — | 152,754 | ||||||
| Conversion of Series A convertible preferred stock into common stock | (7,064,925) | (55,735) | 7,064,925 | 1 | 55,734 | — | — | 55,735 | ||||||
| Issuance of restricted stock | — | — | 204,187 | — | — | — | — | — | ||||||
| Exercise of stock options | — | — | 48,663 | — | 254 | — | — | 254 | ||||||
| Purchases under employee stock purchase plan | — | — | 21,007 | — | 214 | — | — | 214 | ||||||
| Stock-based compensation | — | — | — | — | 6,234 | — | — | 6,234 | ||||||
| Unrealized gain (loss) on investments, net | — | — | — | — | — | (10) | — | (10) | ||||||
| Net loss | — | — | — | — | — | — | (41,567) | (41,567) | ||||||
| Balance at December 31, 2021 | — | — | 29,115,421 | 3 | 228,532 | (10) | (49,742) | 178,783 | ||||||
| Issuance of restricted stock | — | — | 186,727 | — | — | — | — | — | ||||||
| Exercise of stock options | — | — | 81,067 | — | 516 | — | — | 516 | ||||||
| Purchases under employee stock purchase plan | — | — | 178,339 | — | 723 | — | — | 723 | ||||||
| Stock-based compensation | — | — | — | — | 10,336 | — | — | 10,336 | ||||||
| Unrealized gain (loss) on investments, net | — | — | — | — | — | 9 | — | 9 | ||||||
| Net loss | — | — | — | — | — | — | (81,828) | (81,828) | ||||||
| Balance at December 31, 2022 | — | — | 29,561,554 | 3 | 240,107 | (1) | (131,570) | 108,539 | ||||||
| Issuance of restricted stock | — | — | 180,316 | — | — | — | — | — | ||||||
| Exercise of stock options | — | — | 125,192 | — | 937 | — | — | 937 | ||||||
| Issuance of common stock from public offering, net of issuance costs of $10,697 | 5,750,000 | 1 | 161,802 | — | — | 161,803 | ||||||||
| Purchases under employee stock purchase plan | — | — | 249,548 | — | 1,081 | — | — | 1,081 | ||||||
| Stock-based compensation | — | — | — | — | 14,131 | — | — | 14,131 | ||||||
| Unrealized gain (loss) on investments, net | — | — | — | — | — | 1 | — | 1 | ||||||
| Net loss | — | — | — | — | — | — | (117,255) | (117,255) | ||||||
| Balance at December 31, 2023 | — | — | 35,866,610 | $4 | $418,058 | $— | $(248,825) | $169,237 | ||||||
| The accompanying notes are an integral part of these financial statements. | ||||||||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.